OnCo
ideasIdea

A delivery-science moonshot for prevention we already own

Around four in ten cancers are preventable with tools that exist now. This would fund the hard, unglamorous work of getting vaccines, screening and tobacco control to everyone, paid on results.

An ARPA-style programme, but for implementation: it funds and rigorously evaluates ways to reach 90% HPV and hepatitis B vaccine coverage, H. pylori test-and-treat in high-incidence populations, tobacco cessation embedded in lung screening, and alcohol and obesity policy trials. Payments are milestone- and outcome-based (coverage achieved, quitters verified) rather than for papers. The scientific content is behavioural economics, health-systems engineering and policy evaluation, which conventional cancer funders rarely score well.

Hypothesis
A prevention-delivery programme funded at 5% of a national cancer research budget, paying on verified coverage outcomes, lifts HPV vaccine completion and lung-screening uptake in target populations by at least 15 percentage points within five years, at a cost per life-year saved below that of any recently approved oncology drug.
Rationale
Modelling for the WHO cervical cancer elimination strategy shows vaccination plus screening eliminates a cancer within a lifetime; the constraint is delivery, not knowledge. Outcome-based funding has moved coverage in vaccination (Gavi performance-based financing) and in tuberculosis case-finding.
What would test it
Cluster-randomised implementation trials in three regions comparing outcome-paid delivery contracts with standard grant funding for HPV catch-up and lung screening, measuring coverage and cost per additional person covered after two years.
Maturity
speculative
Who has to act
policy
Cost to try
Large (over $50M)
Years to first evidence
5
Bottlenecks it attacks

Key papers

1top

Connected

11top

Pages like this

not linked directly; found by shared links